New Study On Orphan Drugs Partnering Terms and Agreements

332 views

Published on

The report provides an understanding and analysis of how and why companies enter orphan drugs partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors orphan drugs technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
332
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

New Study On Orphan Drugs Partnering Terms and Agreements

  1. 1. Orphan Drugs Partnering Terms and Agreements The Orphan Drugs Partnering Agreements report provides an understanding and access to the orphan drugspartnering deals and agreements entered into by the worlds leading healthcare companies. Trends in orphandrugs partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of developmentOrphan drugs partnering contract documents Top orphan drugs deals by value The OrphanDrugs PartneringTerms and Agreements report provides an understanding and access to the orphan drugs partnering deals andagreements entered into by the worlds leading healthcare companies. The report provides an understandingand analysis of how and why companies enter orphan drugs partnering deals. The majority of deals arediscovery or development stage whereby the licensee obtains a right or an option right to license the licensorsorphan drugs technology. These deals tend to be multicomponent, starting with collaborative R&D, andcommercialization of outcomes. Understanding the flexibility of a prospective partner’s negotiateddeals terms provides critical insight into the negotiation process in terms of what you can expect to achieveduring the negotiation of terms. Whilst many smaller companies will be seeking details of the paymentsclauses, the devil is in the detail in terms of how payments are triggered – contract documents providethis insight where press releases do not. This report contains over 140 links to online copies of actual orphandrugs deals and where available, contract documents as submitted to the Securities Exchange Commission bycompanies and their partners. Contract documents provide the answers to numerous questions about aprospective partner’s flexibility on a wide range of important issues, many of which will have asignificant impact on each party’s ability to derive value from the deal. The initial chapters of thisreport provide an orientation of orphan drugs dealmaking and business activities. Chapter 1 provides anintroduction to the report, whilst Chapter 2 provides an overview of the trends in orphan drugs dealmaking since 2007, including details ofdisclosed headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading orphandrugs deals since 2007. Deals are listed by headline value. Where the deal has an agreement contract publishedat the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive and detailedreview of orphan drugs partnering deals signed and announced since 2007, and where available, a contractdocument is available in the public domain. The chapter is organized by company A-Z, stage of developmentat signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each dealtitle links via Weblink to an online version of the deal record and where available, the contract document,providing easy access to each contract document on demand. The report also includes numerous tables andfigures that illustrate the trends and activities in orphan drugs partnering and dealmaking since 2007. Inconclusion, this report provides everything a prospective dealmaker needs to know about partnering in theresearch, development and commercialization of orphan drugs technologies and products. Report scopeOrphan Drugs Partnering Terms and Agreements is intended to provide the reader with an in-depthunderstanding and access to orphan drugs trends and structure of deals entered into by leading companiesworldwide. Orphan Drugs Partnering Terms and Agreements includes: Trends in orphan drugs dealmakingin the biopharma industry since 2007 Analysis of orphan drugs deal structure Access to headline, upfront,milestone and royalty data Access to 140 orphan drugs deal records The leading orphan drugs deals by valuesince 2007 In Orphan Drugs Partnering Terms and Agreements, the available deals are listed by: CompanyOrphan Drugs Partnering Terms and Agreements
  2. 2. A-Z Headline value Stage of development at signing Deal component type Specific therapy target Each dealtitle links via Weblink to an online version of the deal record and where available, the contract document,providing easy access to each contract document on demand. The Ophan Drugs Partnering Terms andAgreements report provides comprehensive access to available deals and contract documents for over 140orphan drugs deals. Analyzing actual contract agreements allows assessment of the following: What are the precise rightsgranted or optioned? What is actually granted by the agreement to the partner company? What exclusivity isgranted? What is the payment structure for the deal? How aresales and payments audited? What is the dealterm? How are the key terms of the agreement defined? How are IPRs handled and owned? Who isresponsible for commercialization? Who is responsible for development, supply, and manufacture? How isconfidentiality and publication managed? How are disputes to be resolved? Under what conditions can thedeal be terminated? What happens when there is a change of ownership? What sublicensing andsubcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Whichboilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction doesthe company insist upon for agreement law?table Of Contentexecutive Summarychapter 1 – Introductionchapter 2 – Trends In Orphan Drugs Dealmaking2.1. Introduction2.2. Orphan Drugs Partnering Over The Years2.3. Bigpharma Orphan Drugs Dealmaking Activity2.4. Bigpharma Not Active In Orphan Drugs Partnering2.5. Orphan Drugs Partnering By Deal Type2.6. Orphan Drugs Partnering By Stage Of Development2.7. Orphan Drugs Partnering By Cancer Indication2.8. Disclosed Deal Terms For Orphan Drugs Partnering2.8.1 Orphan Drugs Partnering Headline Values2.7.2 Orphan Drugs Deal Upfront Payments2.7.3 Orphan Drugs Deal Milestone Payments2.7.4 Orphan Drugs Royalty Rateschapter 3 – Leading Orphan Drugs Deals3.1. Introduction3.2. Top Orphan Drugs Deals By Valuechapter 4 – Orphan Drugs Dealmaking Directory4.1. IntroductionOrphan Drugs Partnering Terms and Agreements
  3. 3. 4.2. Company A-z4.3. By Stage Of Developmentdiscoverymarketedphase Iphase Iiphase Iiipre-clinicalregistration4.4. By Deal Typeasset Purchasebigpharma Outlicensingco-developmentcollaborative R&dco-marketcontract Serviceco-promotioncradacross-licensingdevelopmentdistributionequity Purchaseevaluationgrantjoint Venturelicensingmanufacturingmarketingmaterial Transferoptionresearchsettlementsub-licensesupplytechnology Transferterminationwarranty4.5. By Therapy Areacardiovascularcentral Nervous SystemdentaldermatologygastrointestinalOrphan Drugs Partnering Terms and Agreements
  4. 4. genetic Disordersgenitourinaryhematologyhospital Careimmunologyinfectivesmetabolicmusculoskeletaloncologyophthalmicspediatricsrespiratorychapter 5 –partnering Resource Center5.1. Online Partnering5.2. Partnering Events5.3. Further Reading On Dealmakingappendicesappendix 1 – Deal Type Definitionsappendix 2 – Example Orphan Drugs Partnering Agreementabout Wildwood Venturescurrent Partneringcurrent Agreementsrecent Report Titles From Currentpartneringorder Form – Therapy Reportsorder Form – ReportsAbout Us:Transparency Market Research is a market intelligence company providing global business informationreports and services. Our exclusive blend of quantitative forecasting and trends analysis providesforward-looking insight for thousands of decision makers. We are privileged with highly experienced team ofAnalysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques togather, and analyze information. Our business offerings represent the latest and the most reliable informationindispensable for businesses to sustain a competitive edge.Contact:ResearchMoz90 State Street,Orphan Drugs Partnering Terms and Agreements
  5. 5. Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usBlog: http://researchmoz.blogspot.com/Website: http://www.researchmoz.us/Orphan Drugs Partnering Terms and Agreements

×